Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements (TBZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00642057
Expanded Access Status : Available
First Posted : March 24, 2008
Last Update Posted : February 9, 2021
Sponsor:
Information provided by (Responsible Party):
Joseph Jankovic, Baylor College of Medicine

Tracking Information
First Submitted Date December 28, 2007
First Posted Date March 24, 2008
Last Update Posted Date February 9, 2021
 
Descriptive Information
Brief Title Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements
Brief Summary Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Detailed Description The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Study Type Expanded Access
Intervention Drug: tetrabenazine
25 mg titrated to optimal dose per patient
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Contacts
Contact: Rory D Mahabir, MBA 713-798-5989 rory.mahabir@bcm.edu
Listed Location Countries Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number NCT00642057
Responsible Party Joseph Jankovic, Baylor College of Medicine
Study Sponsor Joseph Jankovic
Collaborators Not Provided
Investigators Not Provided
PRS Account Baylor College of Medicine
Verification Date February 2021